» Articles » PMID: 12497638

BRCA1 Germline Mutations in Indian Familial Breast Cancer

Overview
Journal Hum Mutat
Specialty Genetics
Date 2002 Dec 24
PMID 12497638
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Germline mutation analysis of BRCA1 gene has demonstrated significant allelic heterogeneity. These differences represent historical influences of migration, population structure and geographic or cultural isolation. To date, there have been no reports of Indian families with mutations in BRCA1. We have screened for mutations in selected coding exons of BRCA1 and their flanking intron regions in three breast or breast and ovarian cancer families with family history of three or more cases of breast cancer under age 45 and/or ovarian cancer at any age. We have also analyzed 10 female patients with sporadic breast cancer regardless of age and family history, as well as 50 unrelated normal individuals as controls. Thus a total of 90 samples were analyzed for BRCA1 mutations using polymerase chain reaction-mediated site directed mutagenesis (PSM) and single stranded conformation polymorphism (SSCP) analysis for various selected exons followed by sequencing of variant bands. Eight point mutations were identified. Two deleterious pathogenic, protein truncating non-sense mutations were detected in exon 11 (E1250X) and exon 20 (E1754X) and six novel and unique amino acid substitutions (F1734S, D1739Y, V1741G, Q1747H, P1749A, R1753K). One complex missense mutation of exon 20 [V1741G; P1749A] was seen in two out of three families and another complex combination of missense and non-sense mutations of the same exon [V1741G; E1754X] was observed in only one family. These complex mutations exist only in breast cancer families but not in control populations of women. Three splice site variants (IVS20+3A>C, IVS20+4A>T, IVS20+5A>T) and two intronic variants (IVS20+21_22insG, IVS20+21T>G) were also detected. In the group of 10 sporadic female patients no mutations were found.

Citing Articles

Genetic Counseling, Testing, and Management of HBOC in India: An Expert Consensus Document from Indian Society of Medical and Pediatric Oncology.

Malhotra H, Kowtal P, Mehra N, Pramank R, Sarin R, Rajkumar T JCO Glob Oncol. 2020; 6:991-1008.

PMID: 32628584 PMC: 7392772. DOI: 10.1200/JGO.19.00381.


Practical consensus recommendation on when to do BRCA testing.

Parikh P, Wadhwa J, Minhas S, Gupta A, Mittal S, Ranjan S South Asian J Cancer. 2018; 7(2):106-109.

PMID: 29721474 PMC: 5909285. DOI: 10.4103/sajc.sajc_112_18.


Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries.

Kwong A, Shin V, Ho J, Kang E, Nakamura S, Teo S J Med Genet. 2015; 53(1):15-23.

PMID: 26187060 PMC: 4681590. DOI: 10.1136/jmedgenet-2015-103132.


Distribution of BRCA1 and BRCA2 Mutations in Asian Patients with Breast Cancer.

Kim H, Choi D J Breast Cancer. 2014; 16(4):357-65.

PMID: 24454456 PMC: 3893336. DOI: 10.4048/jbc.2013.16.4.357.


A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer.

Karami F, Mehdipour P Biomed Res Int. 2013; 2013:928562.

PMID: 24312913 PMC: 3838820. DOI: 10.1155/2013/928562.